Refine your search
Collections
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Mohite, S. K.
- Drug used in Inflammatory Bowel Disease (IBD) - Brief Review
Abstract Views :263 |
PDF Views:0
Authors
Affiliations
1 Rajarambapu College of Pharmacy, Kasegaon, Tal.-Walva, Dist.-Sangli - 415 404, IN
1 Rajarambapu College of Pharmacy, Kasegaon, Tal.-Walva, Dist.-Sangli - 415 404, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 3 (2014), Pagination: 153-161Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. Drug delivery to the appropriate site(s) along the gastrointestinal tract also has been a major challenge, and second-generation agents have been developed with improved drug delivery, increased efficacy, and decreased side effect The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the, symptoms, diagnosis and current treatments for inflammatory bowel disease.Keywords
Inflammatory Bowel Disease (IBD), 5-Aminosalicylates, Corticosteroids, Infliximab, Herbal Drugs, Symptoms, Diagnosis.
References
- Longstreth GF. Definition and classification of irritable bowel syndrome: current consensus and controversies. Gastroenterol. Clin. North Am. 2005; 34: 173-87.
- Drossman DA. Introduction. The Rome Foundation and Rome III. Neurogastroenterol. Motil. 2007; 19: 783-6.
- WHO. International Statistical Classification of Diseases and Related Health Problems, 10th edn. Geneva, Switzerland: World Health Organization, 2007.
- Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978; 2 (6138): 653-4.
- Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol. 2002; 97 (11 Suppl.): S7-26.
- Drossman DA, Douglas A, eds. Rome III: The Functional Gastrointestinal Disorder, 3rd edn.
- McClean, VA, USA: Degnon Associates, 2006. 7 Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig. Dis. Sci. 2002; 47: 225-35.
- Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am. J. Epidemiol. 1995; 142: 76-83.
- Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005; 34: 205-20.
- Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005; 34: 247-55.
- Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol. Clin. North Am. 2005; 34: 281-303.
- Cash BD, Chey WD. Irritable bowel syndrome-an evidence based approach to diagnosis. Aliment. Pharmacol. Ther. 2004; 19: 1235-45.
- Park JM, Choi MG, Kim YS et al. Quality of life of patients with irritable bowel syndrome in Korea. Qual. Life. Res. 2009; 18: 435-46.
- Katsinelos P, Lazaraki G, Kountouras J et al. Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. Eur. J. Gastroenterol. Hepatol. 2009; 21: 183-9.
- Tan YM, Goh KL, Muhidayah R, Ooi CL, Salem O. Prevalence of irritable bowel syndrome in young adult Malaysians: a survey among medical students. J. Gastroenterol. Hepatol. 2003; 18: 1412-16.
- Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment. Pharmacol. Ther. 2004; 20: 339-45.
- Bommelaer G, Dorval E, Denis P et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol. Clin. Biol. 2002; 26: 1118-23.
- World Gastroenterology Organization, 2009 WGO Global Guideline IBD4
- Barnes PJ, Karin M: Nuclear factor-_B. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997, 336, 1066-1071.
- Prantera C, Cottone M, Pallone F: Mesalamine in the treatment of mild to moderate active Crohn's ileitis, results of a randomised multicenter trial. Gastroenterology, 1999, 116, 521-52.
- Camma C, Giunta M, Rosselli M, Cottone M: Mesalamine in the maintenance treatment of Crohn's disease, A meta-analysis adjusted for confounding variables. Gastroenterology, 1997, 113, 1465-1473.
- Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine, a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest, 1998, 101, 1163-1174.
- Meyers S, Sachar DB: Medical therapy of Crohn's disease. In: Inflammatory Bowel Disease. 4th edn., Eds. Kersnar JB, Shorter RG, Williams and Wilkins, Baltimore, 1995, 695-714.
- Aberra FN, Lewis JD, Hass D, Rombeau J, Osborne B, Lichtenstein G: Corticosteroids and immunomodulators, postoperative infectious complication risk in inflammatory bowel disease. Gastroenterology, 2003, 125, 320-327.
- Bello C, Goldstein F, Thornton JJ: Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol, 1991, 86, 460-466.
- Faubion WA Jr, Loftus EV, Harmsen WS, Zinmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease, a population based study. Gastroenterology, 2001, 121, 255-260.
- Vakil N, Sparberg M: Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology, 1989, 96, 62-67.
- Greenberg GR, Feagan BR, Martin F, Sutherland L, Thomson A,Williams N, Nilsson L, Persson T: Oral budesonide for active Crohn's disease. New Eng J Med, 1994, 331, 836-841.
- Hofer KN: Oral budesonide in management of Crohn's disease. Ann Pharmacother, 2003, 37, 1457-1464.
- Aberra FN, Lewis JD, Hass D, Rombeau J, Osborne B, Lichtenstein G: Corticosteroids and immunomodulators, postoperative infectious complication risk in inflammatory bowel disease. Gastroenterology, 2003, 125, 320-327.
- Fernandes-Banares F, Hinojoso J, Sanchez-Lombrana JL: Randomised clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol, 1999, 2, 427-433.
- Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis, 1995, 1, 48-63.
- Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present D, Braakman T, DeWoody K et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor - for Crohn's disease. New Eng J Med, 1997, 337, 1029-1035.
- Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med, 2007, 357, 228-238.
- Watt K, Christofi N, Young R. The detection of antibacterial actions of whole herb tinctures using luminescent Escherichia coli. Phytother Res 2007; 21: 1193-1199.
- Yoshikawa M, Morikawa T, Oominami H, Matsuda H. Absolute stereo structures of olibanumols A, B, C, H, I, and J from olibanum, gum-resin of Boswellia carterii, and inhibitors of nitric oxide production in lipopolysaccharide-activated mouse peritonea macrophages. Chem Pharm Bull (Tokyo) 2009; 57: 957-964
- Chevrier MR, Ryan AE, Lee DY, Zhongze M, Wu-Yan Z, Via CS. Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. Clin Diagn Lab Immunol 2005; 12: 575-580
- Camarda L, Dayton T, Di Stefano V, Pitonzo R, Schillaci D. Chemical composition and antimicrobial activity of some oleogum resin essential oils from Boswellia spp. (Burseraceae). Ann Chim 2007; 97: 837-844.
- Moghtader M, Mansouri I, Salari H, Farahmand A. Chemical composition and antimicrobial activity of the essential oil of bunium persicum boiss. Seed. Iran J Med Aromat Plants Spring 2009; 25: 20-28.
- Shahsavari N, Barzegar M, Sahari MA, Naghdibadi H. Antioxidant activity and chemical characterization of essential oil of Bunium persicum. Plant Foods Hum Nutr 2008; 63: 183-188.
- Kumar VP, Chauhan NS, Padh H, Rajani M. Search for antibacterial and antifungal agents from selected Indian medicinal plants. J Ethnopharmacol 2006; 107: 182-188.
- Francis JA, Raja SN, Nair MG. Bioactive terpenoids and guggulusteroids from Commiphora mukul gum resin of potential anti-inflammatory interest. Chem Biodivers 2004; 1: 1842-1853.
- Saeed MA, Sabir AW. Antibacterial activities of some constituents from oleo-gum-resin of Commiphora mukul. Fitoterapia 2004; 75: 204-208.